Pancreatic Cancer Clinical Trial
Official title:
Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life
Verified date | August 2018 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Specific Aims and Hypotheses:
Aim 1: To test the effect of the "Trial of Ascertaining Individual preferences for Loved
Ones' Role in End-of-life Decisions" (TAILORED) Intervention on family decision-making
self-efficacy at 8 weeks both with respect to the patient's present situation and in a
hypothetical situation in which the patient lacks decision-making capacity.
Hypotheses 1a: Family decision-making self-efficacy will be greater at 8 weeks in pairs that
have undergone the TAILORED Intervention than in pairs receiving the standard information on
advance directives in the patient's present situation.
Hypotheses 1b: Family decision-making self-efficacy will be greater at 8 weeks in pairs that
have undergone the TAILORED Intervention than in pairs receiving the standard information on
advance directives in the hypothetical situation in which the patient lacks decision making
capacity.
Aim 2: To test the effect of the TAILORED Intervention on family psychological outcomes
(depression, caregiver burden, decision making distress).
Hypotheses 2a: Depression will be less at 8 weeks in family members who have undergone the
TAILORED Intervention than in family members who have received the standard information on
advance directives.
Hypotheses 2b: Caregiver burden will be less at 8 weeks in family members who have undergone
the TAILORED Intervention than in family members who have received the standard information
on advance directives.
Hypotheses 2c: Decision-making distress will be less at 8 weeks in family members who have
undergone the TAILORED Intervention than in family members who have received the standard
information on advance directives.
Aim 3: To test the effect of the TAILORED Intervention on patient and family satisfaction
with family decision-making involvement.
Hypothesis 3a: Patient satisfaction with family decision involvement will be greater at 8
weeks in patients who have undergone the TAILORED Intervention than in patients receiving the
standard information on advance directives.
Hypothesis 3b: Family member satisfaction with decision involvement will be greater at 8
weeks in family members who have undergone the TAILORED Intervention than in family members
receiving the standard information on advance directives.
Aim 4: To explore family decision-making self-efficacy and perceptions of the TAILORED
Intervention.
Status | Completed |
Enrollment | 431 |
Est. completion date | March 26, 2014 |
Est. primary completion date | March 26, 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patient Inclusion Criteria 1. Age 18 or older 2. Speaks and reads English 3. Diagnosed by a specialist at either Johns Hopkins Medical Institutions or University of Chicago Medical Center as having ALS or stage III or IV GI or pancreatic cancer. 4. Accompanied to clinic by a family member who may participate in the patient's health care decisions and who patient gives permission to approach for participation in study. 5. Lives within a 2-hour drive of The Johns Hopkins Medical Institutions or The University of Chicago Medical Center 5.G.2. Family Inclusion Criteria 1. Age 18 or older 2. Speaks and reads English 3. Identified by the patient-subject as a family member whom the patient may involve in health care decision making in the present and/or should the patient become too ill to make health care decisions. 4. Person who the patient-subject has granted investigators permission to approach for participation in this study. Exclusion Criteria: - Patient Exclusion Criteria 1. Severe visual impairment that would limit ability to visualize instrument illustrations 2. Cognitive impairment indicated by a Short Portable Mental Status Questionnaire adjusted error score of >5 3. Has no family member who might assist in decision making or family member declines to participate. 4. Is not accompanied to the clinic by family member. 5. G.4. Family Exclusion Criteria 1. Declines to participate. 2. Severe visual impairment that would limit ability to visualize instrument illustrations. 3. Cognitive impairment indicated by a Short Portable Mental Status Questionnaire adjusted error score of >5 |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute of Nursing Research (NINR), University of Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | family decision-making self-efficacy | at 8 weeks after the intervention | ||
Secondary | family psychological outcomes (depression, caregiver burden, decision making distress) | 8 weeks after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|